Application of urolithin A and derivatives thereof in tumor immunotherapy

• Main Authors: LIANG XIAOHONG, LI CHUNYANG, MA SHUAIYA, GAO LIFEN, MA CHUNHONG, CHEN CHAOJIA
• Format: Patent
• Language: Chinese; English
• Published: 21.12.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides application of urolithin A and derivatives thereof in tumor immunotherapy, and belongs to the technical field of biological medicine and molecular biology. According to the application, the research results show that the urolithin A and the derivatives thereof can promote the effector function of CD8 + T cells and other TCR pathway mediated activated effector T cells or artificially prepared effector T cells (including but not limited to CAR-T and TCR-T cells) so as to improve the tumor immunotherapy effect, such that the understanding of the urolithin A is effectively broadened. Regulation and control of the urolithin A on CD8 + T cell functions further reveals interaction of flora metabolites and an immune system, a theoretical basis is provided for deeply excavating more metabolites for regulating and controlling immunity, a promising immunotherapy strategy is provided for tumor patients, and therefore the urolithin A has good practical application value. 本发明提供尿石素A及其衍生物在肿瘤免疫治疗的应用，属于生